Fosamax, Boniva, Actonel - Potential Increased Risk of Esophagus Cancer
Today the FDA notified healthcare professionals and patients about new studies evaluating whether or not Fosamax, Boniva, and Actonel had an increased risk of esophagus cancer.
FDA has not concluded that taking an oral bisphosphonate drug increases the risk of esophageal cancer. FDA will continue to evaluate all available data supporting the safety and effectiveness of bisphosphonate drugs and will update the public when more information becomes available.
Subscribe to:
Post Comments (Atom)
Fosamax In The News
Posts
0 comments:
Post a Comment